22:18:22 EST Thu 30 Nov 2023
Enter Symbol
or Name

Login ID:

News for U:CANF from 2022-12-01 to 2023-11-30 - 32 items News ReleasesIn The NewsOther CAUS
2023-11-30 07:00U:CANFNews ReleaseCan-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
2023-11-21 13:53U:CANFNews ReleaseCan-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
2023-11-21 07:00U:CANFNews ReleaseCan-Fite: Complete Response and 6.9 Years ‚  Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
2023-11-01 07:00U:CANFNews ReleaseCan-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
2023-10-30 07:00U:CANFNews ReleaseCan Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
2023-10-26 07:00U:CANFNews ReleaseCan-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
2023-10-09 07:00U:CANFNews ReleaseCan-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
2023-09-27 07:00U:CANFNews ReleaseCan-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
2023-09-07 07:00U:CANFNews ReleaseCan-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference
2023-08-31 07:00U:CANFNews ReleaseCan-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
2023-08-24 07:10U:CANFNews ReleaseCan-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
2023-08-18 07:00U:CANFNews ReleaseCan-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
2023-07-17 07:00U:CANFNews ReleaseCan-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
2023-06-29 07:00U:CANFNews ReleaseCan-Fite Receives U.S. FDA ¢ € ™s Go Ahead for Piclidenoson Psoriasis Registration Plan
2023-06-13 07:00U:CANFNews ReleaseCan-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
2023-06-02 07:00U:CANFNews ReleaseCan-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
2023-06-01 07:00U:CANFNews ReleaseCan-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
2023-05-30 07:00U:CANFNews ReleaseCan-Fite: Namodenoson ¢ € ™s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
2023-05-15 07:00U:CANFNews ReleaseCan-Fite: Presenting Namodenoson ¢ € ™s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
2023-05-09 07:00U:CANFNews ReleaseCan-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
2023-05-02 07:00U:CANFNews ReleaseInhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
2023-04-24 07:00U:CANFNews ReleaseCan-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
2023-04-10 07:00U:CANFNews ReleaseCan-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
2023-03-30 07:15U:CANFNews ReleaseCan-Fite Reports 2022 Financial Results & Provides Clinical Update
2023-03-16 07:00U:CANFNews ReleaseCan-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
2023-03-13 07:00U:CANFNews ReleaseCan-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
2023-01-24 07:00U:CANFNews ReleaseCan-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies ¢ € ”A Patent Has Been Filed
2023-01-11 09:04U:CANFNews ReleaseCan-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
2023-01-10 07:00U:CANFNews ReleaseCan-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
2022-12-30 16:30U:CANFNews ReleaseCan-Fite Announces ADS Ratio Change
2022-12-28 07:00U:CANFNews ReleaseCan-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
2022-12-27 08:05U:CANFNews ReleaseMultiple Shots On Goal: Can-Fite ƒ ¢ ‚ € ‚ ™s Late-Stage Clinical Pipeline Hits Positive Results